Company Overview of Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC discovers, develops, and distributes therapeutic solutions. The company specializes in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new enzyme. It provides prescription medicines and vaccines, as well as consumer health and animal health products. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
55 Corporate Drive
Bridgewater, NJ 08807
Founded in 1999
Key Executives for Sanofi-Aventis U.S. LLC
Chief Executive Officer of Canada Operations and President of Canada Operations
Chief Executive Officer of Sanofi-Aventis
Chairman of Chattem and Chief Executive Officer of Chattem
President of U S Science and Medical Affairs
President of North America Pharmaceuticals
Compensation as of Fiscal Year 2014.
Sanofi-Aventis U.S. LLC Key Developments
ZAI Lab Limited Signs License Agreement with Sanofi-Aventis
Aug 14 14
ZAI Lab Limited has entered into a global licensing agreement with Sanofi-Aventis U.S. LLC for two novel compounds potential treatment of chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, ZAI Lab will be responsible for global development, manufacturing and commercialization of the two clinical ready novel programs. Sanofi will potentially receive development and regulatory approval milestones and tiered royalties from the global net sales of the licensed products.
Sanofi North America Presents at SelectUSA 2013 Investment Summit, Oct-31-2013 02:15 PM
Oct 29 13
Sanofi North America Presents at SelectUSA 2013 Investment Summit, Oct-31-2013 02:15 PM. Venue: Washington, District Of Columbia, United States. Speakers: Anne Whitaker, CEO.
Covis Pharma to Acquire US Rights from Sanofi-Aventis U.S. LLC for Nilandron(R), Plaquenil(R), Rilutek(R), Uroxatral(R) and Kayexalate(R)
Apr 4 13
Covis Pharma Sarl announced an agreement with sanofi-aventis U.S. LLC and certain of its affiliates to acquire full commercial rights for Nilandron(R) (nilutamide), Plaquenil(R) (hydroxychloroquine), Rilutek(R) (riluzole), Uroxatral(R) (alfuzosin hydrochloride), and Kayexalate(R) (sodium polystyrene sulfate) in the United States. The aggregate sales for these products in the United States in 2012 were $114.6 million. Sanofi will retain the existing rights for these products in countries outside the United States. Terms of the agreement have not been disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|